|Bid||5.35 x 200000|
|Ask||5.40 x 200000|
|Day's range||5.25 - 5.25|
|52-week range||3.92 - 24.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2024 - 26 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
GOLETA, Calif., November 13, 2023--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has appointed Kevin Smith as Inogen’s President and Chief Executive Officer and a member of the Board of Directors, effective immediately, succeeding Nabil Shabshab.
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
GOLETA, Calif., November 09, 2023--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following investor conferences: